Disease Site Breast Disease You have free access to this content Treatment of breast carcinoma in patients with clinically negative axillary lymph nodes using radiotherapy versus axillary dissection (pages 2155–2163)
Naoko Fujimoto, Atsushi Amemiya, Makoto Kondo, Atsuya Takeda and Naoyuki Shigematsu
Version of Record online: 8 OCT 2004 | DOI: 10.1002/cncr.20650
A retrospective analysis was conducted of 1517 patients with early-stage breast carcinoma who underwent breast-conserving therapy. The results obtained from patients who underwent axillary lymph node dissection, compared with patients who received axillary irradiation, showed that most patients could be treated safely with tangential-field irradiation alone.
You have free access to this content Intraductal biopsy for diagnosis and treatment of intraductal lesions of the breast (pages 2164–2169)
Tadaharu Matsunaga, Yoko Kawakami, Kiyoshi Namba and Masahiko Fujii
Version of Record online: 13 OCT 2004 | DOI: 10.1002/cncr.20657
Intraductal breast biopsy exhibited therapeutic efficacy in 54 of 70 patients with intraductal papilloma (77.6%) who had more than 3 years of clinical follow-up. Therapeutic results tended to be less favorable for patients who had intraductal lesions in multiple duct lobular units.
Gastrointestinal Tract You have free access to this content Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin : Results from Intergroup Trial N9741 (pages 2170–2176)
Thierry Delaunoit, Richard M. Goldberg, Daniel J. Sargent, Roscoe F. Morton, Charles S. Fuchs, Brian P. Findlay, Sachdev P. Thomas, Muhammad Salim, Paul L. Schaefer, Philip J. Stella, Erin Green and James A. Mailliard
Version of Record online: 6 OCT 2004 | DOI: 10.1002/cncr.20594
In Intergroup Trial N9741, 5 patients receiving sequential irinotecan plus bolus 5-fluorouracil (5-FU)/leucovorin (LV) (8.2%) and 4 patients receiving oxaliplatin plus bolus 5-FU/LV (8.5%) for advanced colorectal carcinoma (CRC) died within 60 days of study entry. All fatal toxicities developed within 15 days of treatment administration, and all deaths were associated with the simultaneous occurrence of multiple symptoms, which were dominated by Grade ≥ 3 diarrhea. These findings indicate that regimens containing daily bolus 5-FU/LV and oxaliplatin or irinotecan can be associated with severe gastrointestinal toxicity and high mortality rates. Therefore, the authors recommend the use of more tolerable infusional 5-FU–based regimens to treat metastatic CRC.
You have free access to this content Preclinical evaluation of antisense bcl-2 as a chemosensitizer for patients with gastric carcinoma (pages 2177–2186)
Ryungsa Kim, Manabu Emi, Kazuaki Tanabe and Tetsuya Toge
Version of Record online: 8 OCT 2004 | DOI: 10.1002/cncr.20636
The authors conducted a preclinical evaluation of antisense (AS)
bcl-2 as an enhancer of the chemotherapeutic effect in the treatment of patients with gastric carcinoma. Combination treatment with AS bcl-2 and anticancer drugs, including cisplatin and paclitaxel, may be a new strategy for enhancing chemotherapeutic effects. You have free access to this content Morbidity and mortality of colorectal carcinoma surgery differs by insurance status (pages 2187–2194)
Rachel Rapaport Kelz, Phyllis A. Gimotty, Daniel Polsky, Sandra Norman, Douglas Fraker and Angela DeMichele
Version of Record online: 20 SEP 2004 | DOI: 10.1002/cncr.20624
Uninsured patients and Medicaid recipients are more likely to have complications and die after surgery for colorectal carcinoma compared with patients with private insurance. Causes other than comorbid disease and emergent admission type may account for this disparity.
Genitourinary Disease You have free access to this content A renal mass in the setting of a nonrenal malignancy : When is a renal tumor biopsy appropriate? (pages 2195–2201)
Ricardo F. Sánchez-Ortiz, Lydia T. Madsen, Carlos E. Bermejo, Sijin Wen, Yu Shen, David A. Swanson and Christopher G. Wood
Version of Record online: 6 OCT 2004 | DOI: 10.1002/cncr.20638
For patients who presented with a renal mass and another malignancy, metastases to the kidney were only found in those with clinical evidence of progression of their nonrenal primary tumor. A biopsy before surgical extirpation was not indicated in patients with a renal mass and another clinically localized malignancy, as the renal mass rarely represented a metastasis.
You have free access to this content Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma : Results of Intergroup 0159/Cancer and Leukemia Group B 9480 (pages 2202–2208)
Tim A. Ahles, James E. Herndon II, Eric J. Small, Nicholas J. Vogelzang, Alice B. Kornblith, Mark J. Ratain, Walter Stadler, David Palchak, M. Ernest Marshall, George Wilding, Daniel Petrylak and Jimmie C. Holland
Version of Record online: 13 OCT 2004 | DOI: 10.1002/cncr.20655
Assessment of quality of life (QOL) in patients with metastatic hormone-refractory prostate carcinoma treated with one of three doses of suramin revealed improved QOL in the low-dose arm during treatment, a finding that suggests the existence of palliative effects. Using a centralized data collection method, the authors demonstrated that high response rates (90%) for QOL data collection can be achieved in multicenter cooperative trials.
You have free access to this content Preoperative somatic symptoms are associated with disease progression in patients with bladder carcinoma after cystectomy (pages 2209–2213)
Ganesh S. Palapattu, Patrick J. Bastian, Phillip R. Slavney, Mary Ellen Haisfield-Wolfe, Joanne M. Walker, Karlynn BrintzenhofeSzoc, Bruce Trock, James Zabora and Mark P. Schoenberg
Version of Record online: 8 OCT 2004 | DOI: 10.1002/cncr.20639
In the current study, the authors found a significant relation between preoperatively assessed bodily symptoms and bladder carcinoma progression after radical cystectomy. These findings may be linked with factors related to the biology of bladder carcinoma and may potentially have important implications on the diagnosis and management of patients with this disease.
Gynecologic Oncology You have free access to this content Uterine serous and grade 3 endometrioid carcinomas : Is there a survival difference? (pages 2214–2221)
David M. Boruta II, Paola A. Gehrig, Pamela A. Groben, Victoria Bae-Jump, John F. Boggess, Wesley C. Fowler Jr. and Linda Van Le
Version of Record online: 27 SEP 2004 | DOI: 10.1002/cncr.20645
The presence of a serous component in an endometrial carcinoma is reported to be a significant negative prognosticator. The reported overall survival in women with a uterine serous carcinoma comprising > 50% of their tumor is significantly worse compared with women with poorly differentiated endometrioid carcinoma lacking a serous component.
Head and Neck Disease You have free access to this content Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck : An analysis of two Eastern Cooperative Oncology Group randomized trials (pages 2222–2229)
Athanassios Argiris, Yi Li and Arlene Forastiere
Version of Record online: 27 SEP 2004 | DOI: 10.1002/cncr.20640
Platinum agents have been used widely in the treatment of carcinoma of the head and neck. The Eastern Cooperative Oncology Group (ECOG) has conducted two consecutive, Phase III, randomized studies with cisplatin-based doublets (cisplatin plus 5-fluorouracil and cisplatin plus paclitaxel) in patients with recurrent/metastatic squamous cell carcinoma of the head and neck. In the current study, the authors analyzed data from these two studies to evaluate prognostic factors and long-term survival in patients with recurrent or metastatic head and neck carcinoma.
Hematologic Malignancies You have free access to this content Hematopoietic stem cell transplantation among patients with leukemia of all ages in Texas (pages 2230–2238)
Jessica P. Hwang, Tony P. Lam, Deborah S. Cohen, Michele L. Donato and Jane M. Geraci
Version of Record online: 13 OCT 2004 | DOI: 10.1002/cncr.20628
Self-paid patients with leukemia had the highest rate of hematopoietic stem cell transplantation (HSCT), whereas Medicare patients had the lowest rate. However, logistic regression showed that there were no statistically significant associations between payer status or ethnicity and receipt of HSCT. The findings in the current study were surprising because similar studies had shown differences in receipt of HSCT by ethnicity and insurance.
You have free access to this content Anagrelide for thrombocytosis in myeloproliferative disorders : A prospective study to assess efficacy and adverse event profile (pages 2239–2246)
Michael Steurer, Guenther Gastl, Wieslaw-Wiktor Jedrzejczak, Robert Pytlik, Werner Lin, Ernst Schlögl and Heinz Gisslinger
Version of Record online: 8 OCT 2004 | DOI: 10.1002/cncr.20646
In a prospective Phase II trial, treatment with anagrelide resulted in a rapid decrease inf platelet counts from a median baseline platelet count of 743 × 10
9/L to a median platelet count of 441 × 10 9/L after 6 months ( P < 0.0001). The decrease inf platelet count was accompanied by a significant decrease in major and minor thromboembolic complications. Anagrelide was well tolerated, but concomitant administration with acetylsalicylic acid may increase bleeding tendency. Melanoma You have free access to this content Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma (pages 2247–2256)
Albrecht Reichle, Klaus Bross, Thomas Vogt, Frauke Bataille, Peter Wild, Anna Berand, Stefan W. Krause and Reinhard Andreesen
Version of Record online: 6 OCT 2004 | DOI: 10.1002/cncr.20574
The authors conducted a Phase II trial of a continuously administered molecularly targeted treatment regimen (pioglitazone plus rofecoxib) combined with sequentially added trofosfamide for patients with previously treated metastatic melanoma or soft tissue sarcoma. No major side effects were observed. Objective responses and disease stabilization lasting longer than 6 months were noted in 11% and 11%, respectively, of all patients with melanoma and in 19% and 14%, respectively, of all patients with soft tissue sarcoma. In addition, both normal C-reactive protein (CRP) levels and CRP levels that decreased by > 30% during the 14-day biomodulator pretreatment period were found to be predictive of prolonged progression-free survival.
Neuro-Oncology You have free access to this content Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma (pages 2257–2260)
Dong-Wan Kim, Yo-Han Jo, Jee Hyun Kim, Hong-Gyun Wu, Chae Seo Rhee, Chol Hee Lee, Tae-You Kim, Dae Seog Heo, Yung-Jue Bang and Noe Kyeong Kim
Version of Record online: 13 OCT 2004 | DOI: 10.1002/cncr.20648
In the current study, the combination of etoposide, ifosfamide, and cisplatin (VIP) served as an active neoadjuvant treatment regimen in the treatment of patients with olfactory neuroblastoma. The VIP regimen yielded an objective response rate of 82% (9 of 11 patients).
Sarcoma You have free access to this content Phase I clinical trial of fixed–dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation (pages 2261–2269)
José M. Buesa, Raquel Losa, Aida Fernández, Marta Sierra, Emilio Esteban, Ángela Díaz, Antonio López-Pousa and Joaquín Fra
Version of Record online: 13 OCT 2004 | DOI: 10.1002/cncr.20612
In the current Phase I trial, the authors investigated the efficacy and safety of a regimen containing gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma. Based on the results of this trial, the authors recommend the use of 1800 mg/m
2 gemcitabine administered via 3-hour infusion followed by 500 mg/m 2 dacarbazine administered intravenously over the course of 20 minutes. Liver toxicity, which never exceeded Grade 3 in terms of its severity, was the dose-limiting side effect. Due to the objective activity of the study regimen in the current trial, further investigation may be warranted. You have free access to this content Validation of the postoperative nomogram for 12-year sarcoma-specific mortality (pages 2270–2275)
Fritz C. Eilber, Murray F. Brennan, Frederick R. Eilber, Sarah M. Dry, Samuel Singer and Michael W. Kattan
Version of Record online: 13 OCT 2004 | DOI: 10.1002/cncr.20570
A nomogram that was developed to predict sarcoma-specific death had not yet been validated in an external patient cohort. When applied to prospectively followed adult patients at an external institution, this nomogram provided accurate survival predictions and thus was validated.
Discipline Epidemiology You have free access to this content Effects of cancer history and comorbid conditions on mortality and healthcare use among older cancer survivors (pages 2276–2284)
Pearl H. Seo, Carl F. Pieper and Harvey Jay Cohen
Version of Record online: 6 OCT 2004 | DOI: 10.1002/cncr.20606
In the current study, the authors compared a group of older cancer survivors with a community-based cohort of individuals who had no history of malignancy and found that a history of malignant disease had limited influence on healthcare use and mortality. Efforts aimed at improving health-related outcomes in older cancer survivors should continue to focus on attenuating the impact of comorbid conditions.
You have free access to this content Increasing mortality rates of common malignancies in Colombia : An emerging problem (pages 2285–2292)
Marion Piñeros, Gustavo Hernández and Freddie Bray
Version of Record online: 20 SEP 2004 | DOI: 10.1002/cncr.20607
In what to their knowledge is the first report of national cancer mortality trends in Colombia covering 1981–1996, the authors highlighted the increasing trends for a number of common neoplasms in the last decade, and discussed possible explanations for such observations. To counter the increasing burden, the implementation of cancer control strategies was imperative in Colombia, as was the provision of high-quality data.
You have free access to this content Adult glioma incidence trends in the United States, 1977–2000 (pages 2293–2299)
Kenneth R. Hess, Kristine R. Broglio and Melissa L. Bondy
Version of Record online: 8 OCT 2004 | DOI: 10.1002/cncr.20621
The current analysis formally tested for interactions in incidence trends in adult gliomas between 1977 and 2000 using Surveillance, Epidemiology, and End Results program data.
Medical Oncology You have free access to this content Invasive aspergillosis in patients with solid tumors (pages 2300–2302)
Norio Ohmagari, Isaam I. Raad, Ray Hachem and Dimitrios P. Kontoyiannis
Version of Record online: 27 SEP 2004 | DOI: 10.1002/cncr.20647
Invasive aspergillosis in patients with solid tumors is rarely reported. In the current study, the authors retrospectively studied 13 cancer patients with invasive aspergillosis. Seven patients had brain tumors and six had received systemic steroids. Underlying neutropenia was reported very rarely. The majority of patients (54%) responded to antifungal treatment.
Pathology You have free access to this content Measuring circulating neuroblastoma cells by quantitative reverse transcriptase–polymerase chain reaction analysis : Correlation with its paired bone marrow and standard disease markers (pages 2303–2308)
Irene Y. Cheung, Arvind Sahota and Nai-Kong V. Cheung
Version of Record online: 13 OCT 2004 | DOI: 10.1002/cncr.20660
One hundred twenty pairs of bone marrow and peripheral blood specimens from patients with Stage 4 neuroblastoma were assayed for tumor cell content by quantitative reverse transcriptase–polymerase chain reaction analysis of GD2 synthase mRNA. Monitoring this molecular marker in blood to complement tumor surveillance in the bone marrow can be informative.
You have free access to this content A highly sensitive and quantitative telomerase activity assay with pancreatic juice is useful for diagnosis of pancreatic carcinoma without problems due to polymerase chain reaction inhibitors : Analysis of 100 samples of pancreatic juice from consecutive patients (pages 2309–2317)
Kenoki Ohuchida, Kazuhiro Mizumoto, Nami Ishikawa, Norihiro Sato, Eishi Nagai, Koji Yamaguchi, Hideki Takaishi, Toshinori Ide and Masao Tanaka
Version of Record online: 8 OCT 2004 | DOI: 10.1002/cncr.20649
Telomeric repeat amplification protocol/hybridization protection assay (TRAP/HPA) can detect weak telomerase activity in pancreatic juice without problems due to polymerase chain reaction inhibitors. Analysis of 100 samples of pancreatic juice with TRAP/HPA suggested that this assay is a promising approach for diagnosis of pancreatic carcinoma.
You have free access to this content Small cell astrocytoma: An aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma (pages 2318–2326)
Arie Perry, Kenneth D. Aldape, David H. George and Peter C. Burger
Version of Record online: 6 OCT 2004 | DOI: 10.1002/cncr.20625
High-grade, small cell astrocytoma is an aggressive variant that often is misdiagnosed as anaplastic oligodendroglioma. A study of 71 patients showed that 1) some high-grade, small cell astrocytomas present as nonenhancing masses with no endothelial hyperplasia or necrosis; 2) their clinical behavior is that of a glioblastoma, even when they have Grade III histology; 3) they lack 1p/19q codeletions but show epidermal growth factor receptor (EGFR) amplification (69%) and 10q deletion (97%); and 4) 50% express the constitutively activated mutant form of EGFR, vIII.
Psychological Oncology You have free access to this content A multicenter study of supportive-expressive group therapy for women with BRCA1/BRCA2 mutations (pages 2327–2340)
Mary Jane Esplen, Jon Hunter, Molyn Leszcz, Ellen Warner, Steven Narod, Kelly Metcalfe, Gord Glendon, Kate Butler, Alexander Liede, Mary Anne Young, Stephanie Kieffer, Lisa DiProspero, Ellen Irwin and Jiahui Wong
Version of Record online: 11 OCT 2004 | DOI: 10.1002/cncr.20661
Female BRCA1/BRCA2 mutation carriers participated in and demonstrated improvement on a number of indicators from a specifically designed supportive-expressive group therapy intervention that focused on the unique challenges of receiving personal genetic information. A significant number of decisions were made concerning prophylactic surgery and significant improvements were observed in psychosocial functioning. Knowledge and screening levels were high at baseline and were maintained throughout the intervention.
Translational Research You have free access to this content Pancreatic carcinoma cells express neuropilins and vascular endothelial growth factor, but not vascular endothelial growth factor receptors (pages 2341–2350)
Min Li, Hui Yang, Hong Chai, William E. Fisher, Xiaoping Wang, F. Charles Brunicardi, Qizhi Yao and Changyi Chen
Version of Record online: 8 OCT 2004 | DOI: 10.1002/cncr.20634
Neuropilins (NRPs) are coreceptors of vascular endothelial growth factor (VEGF). In the current study, the human pancreatic carcinoma cell line Panc-1 and adenocarcinoma tissue specimens expressed high levels of NRP-1 and VEGF, but not VEGF receptors (VEGFRs). Exogenous VEGF significantly increased NRP-1-mediated, but not VEGFR-mediated, Panc-1 cell proliferation, indicating that NRP-1 may be involved in the pathogenesis of pancreatic carcinoma.
You have free access to this content Nuclear factor-κB and IκB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis (pages 2351–2362)
Lan Li, Bharat B. Aggarwal, Shishir Shishodia, James Abbruzzese and Razelle Kurzrock
Version of Record online: 8 OCT 2004 | DOI: 10.1002/cncr.20605
Pancreatic carcinoma is a lethal malignancy, with the best available therapeutic option—gemcitabine—yielding response rates of < 10%. Because nuclear factor-κB (NF-κB) has been determined to play a role in cell survival and proliferation in human pancreatic carcinoma, this transcription factor is a potential therapeutic target. In the current study, curcumin was found to down-regulate NF-κB and growth control molecules induced by NF-κB in human pancreatic cells, and these effects were accompanied by marked growth inhibition and apoptosis. Through these findings, the authors provided a biologic rationale for the treatment of patients with pancreatic carcinoma using this nontoxic phytochemical.